Ultimovacs Q1 2024: Survival mode - Redeye

Redeye comments on Ultimovacs’ Q1 2024 report, following its INITIUM top-line failure and announced cost-cutting measures. The company now has a funding runway until Q4 2025e, enabling it to post FOCUS and DOVACC readouts before potentially raising more capital. We judge these readouts to be critical, and negative results would likely erode investor confidence further.

Länk till analysen i sin helhet: https://www.redeye.se/research/1004006/ultimovacs-q1-2024-survival-mode?utm_source=finwire&utm_medium=RSS